Home > HP (current issue) > News and research update / News Centre | Search

PJ Online homeHospital Pharmacist
2007;14:281
October 2007

Hospital Pharmacist back issues

News summary


Pharmacist-led reconciliation backed by draft NICE guidance

Hospital pharmacies may provide an admissions service seven days a week

Hospital pharmacies may provide an admissions service seven days a week

A pharmacist should be involved in reconciling a patient's medicines as soon as possible after admission to hospital, according to draft guidance issued by the National Institute for Health and Clinical Excellence.

In collaboration with the National Patient Safety Agency, NICE examined all available evidence for using medicine reconciliation systems, and agreed that using a medicine reconciliation template was effective in preventing medication errors at the point of hospital admission.

Moreover, the involvement of a pharmacist offers the benefit of medicine review, in addition to medicines reconciliation.

The guidance says that information technology (IT) systems could be used to reduce the risk of transcription errors, and improve communication between primary and secondary care.

However, IT cannot replace the need for a trained person checking what the patient is actually taking, and that it is prescribed appropriately.

David Cousins, head of medication safety at the NPSA, commented: “There is already worldwide recognition that medicines reconciliation is important. However for the first time, this guidance is acknowledging the evidence that involving a pharmacist within a few hours of a patient’s admission can bring about additional benefits.”

He went on to confirm that many hospital pharmacies already employ pharmacists in admissions units, however they may need to consider extending this service to seven days a week. He concluded: “Individual trusts need to examine the pattern of their own medication incident reports, to compare how many occurred when a pharmacist was involved in reconciliation, and how many occurred when they were not.”

The final guidance is expected to be published in December 2007.

Back to Top


©The Pharmaceutical Journal